PEMBROLIZUMAB , Adagloxad simolenin with adjuvant, CAPECITABINE clinical trials

The GLORIA Study: A Phase 3, Randomized, Open-Label Study of the Anti-Globo H Vaccine Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients with High-Risk, Early-Stage Globo H-Positive Triple Negative Breast Cancer

The GLORIA study is looking at a new vaccine, Adagloxad Simolenin, for people with a type of breast cancer called triple-negative breast cancer that has a specific marker called Globo H. It aims to see if this vaccine, given after initial treatment, can help prevent the cancer from coming back.